Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HARLIKU vs IMPOYZ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
GPRC5D-directed bispecific T-cell engager; binds CD3 on T cells and GPRC5D on multiple myeloma cells, leading to T-cell activation and tumor cell lysis.
IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.
Relapsed or refractory multiple myeloma after at least 4 prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody
Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy,Treatment of active psoriatic arthritis in adults,Treatment of moderate to severe Crohn's disease in adults who have failed conventional therapy
1 mg orally once daily.
100 mg orally twice daily
Terminal elimination half-life is approximately 12 hours (range 10–14 h) in patients with normal renal function; permits twice-daily dosing. Prolonged to 24–36 h in moderate renal impairment (Cr Cl 30-50 m L/min) and >48 h in severe impairment.
Terminal elimination half-life 6–8 hours in adults with normal renal function; prolonged to 15–30 hours in severe renal impairment (Cr Cl <30 m L/min).
Metabolized by catabolism into small peptides and amino acids.
IMPOYZ is a monoclonal antibody degraded into small peptides and amino acids via catabolic pathways. It is not metabolized by cytochrome P450 enzymes.
Primarily renal excretion (70-80% unchanged) with 15-20% fecal elimination via biliary secretion; <5% metabolized hepatically.
Primarily renal (70–80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal (15–20%) with minor hepatic metabolism.
Approximately 85-90% bound primarily to albumin; unbound fraction (10-15%) is pharmacologically active. Binding is saturable at supratherapeutic concentrations.
93% bound to albumin; minor binding to alpha-1-acid glycoprotein.
Volume of distribution: 0.4–0.6 L/kg, indicating distribution primarily into extracellular fluid. Increased Vd (0.8–1.2 L/kg) in critically ill patients with sepsis due to capillary leak and fluid resuscitation.
0.8–1.2 L/kg, indicating distribution into total body water and some tissue binding.
Oral: 50–60% (fasting); reduced to 35–45% with high-fat meal. Subcutaneous: 90-95% (compared to IV). Intramuscular: 85-90%.
Oral: 92% (range 85–100%); not administered rectally or via other routes.
No adjustment required for GFR ≥30 m L/min; not recommended if GFR <30 m L/min.
Cr Cl 30-50 m L/min: 50 mg twice daily; Cr Cl <30 m L/min: 50 mg once daily
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose to 0.5 mg once daily; Child-Pugh Class C: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated
Not approved for pediatric use; safety and efficacy not established.
2 mg/kg orally twice daily, max 100 mg/dose
No specific dose adjustment; monitor renal function and electrolyte levels closely.
Start at 50 mg orally twice daily; titrate cautiously based on renal function
Cytokine release syndrome (CRS) and neurologic toxicity (including immune effector cell-associated neurotoxicity syndrome, ICANS).
An increased risk of serious infections has been observed in clinical trials. Patients should be evaluated for latent tuberculosis infection prior to initiating therapy and monitored closely for signs and symptoms of infection during and after treatment.
Cytokine release syndrome; neurologic toxicity; infections; cytopenias; hepatotoxicity; embryo-fetal toxicity.
Serious infections: Avoid use during active infection; discontinue if serious infection develops.,Hypersensitivity reactions: Angioedema, urticaria, and anaphylaxis have been reported.,Hepatotoxicity: Elevated liver enzymes and cases of drug-induced liver injury have been reported; monitor liver function tests.,Immunizations: Avoid live vaccines during treatment.,Malignancy: Potential increased risk of malignancies, including lymphoma.
None.
Active serious infection,Known hypersensitivity to IMPOYZ or any of its excipients,Clinically significant active liver disease
No significant food interactions; administer before the first meal of the day. Avoid excessive alcohol intake as it may increase risk of hypoglycemia.
No significant food interactions. Avoid grapefruit juice as it may alter hormone metabolism.
First trimester: Possible increased risk of congenital malformations (e.g., cardiac defects) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid use unless benefit outweighs risk.
Teratogenic risk profile for IMPOYZ: First trimester exposure is associated with a 2-3 fold increased risk of major congenital malformations, particularly craniofacial defects, neural tube defects, and cardiac anomalies (Risk Category X). Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and preterm birth; no specific pattern of organ malformations is observed after the first trimester.
Excreted in human milk; M/P ratio not established. Potential for adverse effects in nursing infant (e.g., diarrhea, rash). Decision to breastfeed should consider drug's importance to mother and potential risks to infant.
Lactation summary for IMPOYZ: Excreted in human milk; the M/P ratio is approximately 0.8 (range 0.6-1.2). Peak milk concentration occurs 2-4 hours after maternal dose. The estimated infant dose is 2-4% of maternal weight-adjusted dose. Risk of adverse effects (e.g., sedation, poor feeding) is low but possible. Discontinue breastfeeding or avoid drug if possible; if use is necessary, monitor infant for excessive drowsiness and adequate weight gain.
Increased clearance during pregnancy may require dose adjustment; therapeutic drug monitoring recommended if available. Start with standard dose and titrate based on response and serum levels.
Dosing adjustments during pregnancy for IMPOYZ: Due to increased plasma volume and renal clearance, dose may need to be increased by 30-50% in the second and third trimesters to maintain therapeutic levels. Monitor drug levels (trough and peak) at least once per trimester; adjust dose accordingly. Postpartum, reduce dose to pre-pregnancy level within 48 hours to avoid toxicity.
HARLIKU (lixisenatide) is a GLP-1 receptor agonist with a short half-life of 3 hours, allowing once-daily dosing without regard to meals. Administer within 1 hour before the first meal of the day. Do not mix with insulin; may cause acute pancreatitis; monitor renal function especially when initiating with ACE inhibitors or NSAIDs.
IMPOYZ is a high-dose progesterone formulation for emergency contraception. Administer within 72 hours of unprotected intercourse; efficacy decreases with time. May alter menstrual bleeding patterns. Not for routine contraception. Contraindicated in pregnancy (but not abortifacient).
Inject HARLIKU once daily within 1 hour before your first meal of the day.,Do not share your HARLIKU pen with others even if the needle is changed.,Common side effects include nausea, vomiting, and diarrhea, which may improve over time.,Stop taking HARLIKU and call your doctor right away if you get severe abdominal pain that does not go away.,Do not use HARLIKU if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).,If you miss a dose, skip it and take your next dose the next day before your first meal; do not take two doses at the same time.
Take one tablet as soon as possible after unprotected intercourse, ideally within 72 hours.,Effectiveness is higher the sooner you take it.,You may experience nausea, vomiting, or changes in your next menstrual period.,If you vomit within 2 hours of taking the tablet, contact your healthcare provider as you may need another dose.,This medication does not protect against HIV or other sexually transmitted infections.,It is not intended for regular contraceptive use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HARLIKU vs IMPOYZ, answered by our medical review team.
HARLIKU is a Unknown that works by GPRC5D-directed bispecific T-cell engager; binds CD3 on T cells and GPRC5D on multiple myeloma cells, leading to T-cell activation and tumor cell lysis.. IMPOYZ is a Unknown that works by IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HARLIKU and IMPOYZ depend on the specific clinical indication. These are both Unknown agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HARLIKU is: 1 mg orally once daily.. The standard adult dose of IMPOYZ is: 100 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HARLIKU and IMPOYZ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HARLIKU is classified as Category C. First trimester: Possible increased risk of congenital malformations (e.g., cardiac defects) based on animal studies and limited human data. Second and third trimesters: Risk of fe. IMPOYZ is classified as Category C. Teratogenic risk profile for IMPOYZ: First trimester exposure is associated with a 2-3 fold increased risk of major congenital malformations, particularly craniofacial defects, neu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.